User Name Password

back to homepage

Sofame Technologies (SDW.V) - ambitious, but high risk growth strategy

Update by Objective Capital , Aug 24, 2009 (login for full report)
Click for previous reports on this company
Questions? Contact our analyst

Key Points:

  • Profit deferred... again
    The latest results for 3Q09 showed a marked improvement over the previous two quarters and a major improvement on 3Q08, yet the company still posted a net operating loss. Cumulatively, while the results for the 9 month period to 30 June 2009 show revenue to be 32.2% ahead at C$2.16m and gross profit 38.1% better at C$901k, the operating loss widened from C$897k to C$1.75m. Our estimates indicate that the company will incur a further loss for 4Q09, even though revenues should be over C$1m.

  • New personnel, waiting for the cavalry
    New key sales personnel were appointed at end of April in an attempt to reduce the long sales cycle involved in its custom-engineered products and in early May Michel Brisson assumed the role of President and CEO. Although these changes are positive for the company, we don’t see them making much impact until the broader economy improves. Over the last two months, there have been the first signs that the housing market in the US is starting to stabilize and could be the harbinger of better news in 2010. However, the capital goods cycle is likely to lag and so Sofame may not benefit until later. In any case, a higher gas price would act as a more immediate galvanizer to persuade wavering customers of the cost benefit

  • No distribution without representation
    Four new SMRs have been added in North America since October 2008 and one SMR in Mexico. North America now has a total of 18 SMRs. Where organizations have multiple plants, Sofame has tried to increase effectiveness by developing relationships at head office as well as local level. Initiatives to reduce the sales cycle by supporting SMRs directly with Sofame’s own technical personnel are likely to become evident from 4Q09 onwards.

  • Patent pending
    A previous patent on the Sofame steam pump expired and is in the process of being upgraded. Management thinks this could make a major difference to the business given that the product has a price tag of around US$750k, a gross margin of 40 percent and wide application. However, this is not likely to make any impact before 2011.

  • Capital raising deferred... but not forgotten
    The C$5m capital raising that was to have gone ahead in July has been shelved. However, on the basis of our core forecasts it is but a plan postponed - only on the basis of our most optimistic forecasts will the company not require further funding; either new equity, further bank lending facilities, or a mixture of both. Management has put the infrastructure in place (and the costs associated that go with that) in order to secure some highly impressive revenue growth but these ‘orders’ have yet to translate into sales.

    With a fundamental deterioration in its cost structure (the true fixed element of its administrative and selling and marketing expense is in excess of C$2m but probably nearer C$3m), the business will have to run exceedingly fast just to stay still. Its cost structure seems to imply breakeven sales of around C$7.0m in 2010, more than double likely 2009 sales.

    Highly geared operationally, there does not appear to be a Plan B. The step change in revenues promised in its business plan in 2008 are now not an option, they are a necessity.

  • Earnings, earnings…
    On the basis of our core projections we estimate 2010 earnings of C$24k and EPS of C$0.00024 (C$0.00019, fully diluted). Our core 2011 earnings are estimated at C$1.1m and EPS of C$0.0107 (C$0.0084, fully diluted) , i.e. 2011 P/E ratios of 7.5x and 9.5x, respectively.

  • “Do ya’ deliver?”
    In terms of valuation, the current share price actually reflects our reduced expectations but not the effect of further equity dilution should management decide to go down that funding route. The risk at this juncture is that if sales do not materialize as envisaged and the cost of new funding is prohibitive i.e. too dilutive, both could severely punish our core valuation estimate. On a brighter note, there is also considerable potential upside in the value of equity but the rub is whether management can actually deliver the sales in 2010.

Free registration required for full report

SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE!

Objective, Independent, Experienced.
Research you can trust!

Yes! Subscribe me for the latest stock research from Objective.
Email address
My Password
My information:
First Name
Family Name
Title:
Job title:
Job function:
Industry:
I am a:
 
To receive occasional printed reports complete your mailing address:
 
Company Name (if any)
Address
 
 
City
Postcode/Zip
Country

Please Read Objective's Terms of Use.


Balkan Resources (Private) - exploring the Perlati copper deposit in Albania
Oct 09, 2009 | Previous Reports

Scancell Holdings (SCLP.PLUS) - differentiated technology and a focused plan offer ingredients for success
Sep 08, 2009 | Previous Reports

Sofame Technologies (SDW.V) - ambitious, but high risk growth strategy
Aug 24, 2009 | Previous Reports

Soho Resources (SOH.V) - substantial upgrade to total resource
Aug 19, 2009 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons
Nov 18, 2008 | Previous Reports

Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy
Nov 07, 2008 | Previous Reports

LiDCO (LID.L) - half year results show early signs of being on track
Oct 30, 2008 | Previous Reports

OCCASIONAL PAPERS

Albania - revisting old frontiers
October, 2008

The rise of independent research (IR Magazine)
March, 2006

Presentation to 2005 AIM Conference
Sept 26, 2005

The Role of Sponsored Research
June 22, 2005

Objective's Corporate Brochure
July 01, 2004

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839

About Us | Contact Us
Latest Analysis | Register Free | Archives
 
Copyright 2004 Objective Capital. All rights reserved.
Terms of Use | Privacy Policy | Disclaimer